CoChat

Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index; none of the 48 sources its claims cite is checked for support yet.

Abstract

Background: Plasmodium vivax occurs as a latent infection of liver and a patent infection of red blood cells. Radical cure requires both blood schizontocidal and hypnozoitocidal chemotherapies. The hypnozoitocidal therapies available are primaquine and tafenoquine, 8-aminoquinoline drugs that can provoke threatening acute hemolytic anemia in patients having an X-linked G6PD-deficiency. Heterozygous females may screen as G6PD-normal prior to radical cure and go on to experience hemolytic crisis. Methods & findings: This study examined G6PD phenotypes in 1928 female subjects living in malarious Sumba Island in eastern Indonesia to ascertain the prevalence of females vulnerable to diagnostic misclassification as G6PD-normal. All 367 (19%) females having <80% G6PD normal activity were genotyped. Among those, 103 (28%) were G6PD wild type, 251 (68·4%) were heterozygous, three (0·8%) were compound heterozygotes, and ten (2·7%) were homozygous deficient. The variants Vanua Lava, Viangchan, Coimbra, Chatham, and Kaiping occurred among them. Below the 70% of normal G6PD activity threshold, just 18 (8%) were G6PD-normal and 214 (92%) were G6PD-deficient. Among the 31 females with <30% G6PD normal activity were all ten homozygotes, all three compound heterozygotes, and just 18 were heterozygotes (7% of those). Conclusions: In this population, most G6PD heterozygosity in females occurred between 30% and 70% of normal (69·3%; 183/264). The prevalence of females at risk of G6PD misclassification as normal by qualitative screening was 9·5% (183/1928). Qualitative G6PD screening prior to 8-aminoquinoline therapies against P. vivax may leave one in ten females at risk of hemolytic crisis, which may be remedied by point-of-care quantitative tests.

Overview

CoChat Summary

TL;DR

In 1,928 non-anemic females on Sumba Island, Indonesia, most G6PD deficiency was heterozygous and fell between 30% and 70% of normal activity, a range poorly detected by qualitative CareStart screening. Qualitative G6PD screening before 8-aminoquinoline radical cure may leave about one in ten females (9.5%) at risk of being misclassified as normal and thus vulnerable to hemolytic crisis.

Key findings

  • Of 367 females with <80% normal G6PD activity who were genotyped, 103 (28%) were G6PD wild type, 251 (68.4%) were heterozygous, 3 (0.8%) were compound heterozygotes, and 10 (2.7%) were homozygous deficient; variants included Vanua Lava, Viangchan, Coimbra, Chatham, and Kaiping.
  • Below the 70% activity threshold, 214/232 (92%) were genotype-confirmed G6PD-deficient and 18 (8%) were G6PD-normal; among 31 females with <30% activity were all 10 homozygotes, all 3 compound heterozygotes, and 18 heterozygotes (7% of heterozygotes).
  • Among 251 heterozygotes, 183 (73%) occurred between 30% and 70% of normal activity; the prevalence of females at risk of G6PD misclassification as normal by qualitative screening was 9.5% (183/1928).
  • The CareStart qualitative test detected only 33 of 183 (18.0%) heterozygotes with 30–70% activity as G6PD-deficient; at the 70% threshold, sensitivity was 25.1% (95% CI 19.7–31.2), specificity 96.8% (95% CI 95.8–97.6), positive predictive value 21.4% (95% CI 16.2–27.7), and negative predictive value 97.4% (95% CI 97.2–97.5).

Methods

  • Cross-sectional prevalence survey conducted in April 2015 in Southwest Sumba, eastern Indonesia (villages Wainyapu, Waiha, and Umbu Ngedo); healthy females ≥6 years old with informed consent were included, and 1,928 of 2,056 screened females had hemoglobin ≥10 g/dL and were analyzed.
  • G6PD qualitative testing used the CareStart rapid diagnostic test at point of care; quantitative G6PD activity was measured with the Trinity Biotech spectrophotometric assay as the reference; genotyping was restricted to samples with <80% normal activity using PCR-RFLP for common variants and whole-gene/next-generation sequencing for undigested samples.
  • Analyses were performed in R; 100% activity was defined as the mean among samples ≥5 U/g Hb, with diagnostic thresholds set at 10%, 30%, 70%, and 80%; the study assessed CareStart performance against quantitative testing and genotype, using Fisher’s exact test for G6PD prevalence.

Limitations

  • The paper states that the study did not compare the Kcat of G6PD from genotypically G6PD-normal and heterozygous females with G6PD activities below 80%, which could help fine-tune hemolytic risk in heterozygous females under oxidative stress.
  • The paper states that the actual safety threshold of G6PD activity for primaquine or tafenoquine has not been determined in practice or clinical research on heterozygotes, and that the findings do not offer assurance of safety at a 70% activity threshold.
  • Evident from the text: the design was cross-sectional without clinical hemolysis outcomes; genotyping was limited to samples below 80% activity, and some samples negative for the analyzed SNPs were not whole-gene sequenced (ND, presumed G6PD-normal); quantitative G6PD readings were done once per sample.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pntd.0009610

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Survey process and sample analysis.
Fig 1 Survey process and sample analysis.CC BY · PubMed Central
Fig 2 G6PD activity distribution and malaria microscopy positivity in the survey.
Fig 2 G6PD activity distribution and malaria microscopy positivity in the survey.CC BY · PubMed Central
Fig 3 Genotypes identified among the subjects having <80% of normal G6PD activity and that phenotype illustrated in relation to 30% and 70% of normal activity thresholds. CO, VC, and VL Hom are Coimbra, Viangchan, and Vanua Lava homozygous respectively. CO, VC, CT and VL Het are Coimbra, Viangchan, Chatham and Vanua Lava heterozygous respectively. VL & CT and VL & VC represent the 3 compound heterozygotes of those variants. The ND lane represent subjects negative for the G6PD variant SNPs analyzed, but not whole gene sequenced, whereas the Normal lane represents those whole gene sequenced as wild type G6PD. The black dots represent outliers calculated from the boxplot whereas the pink outliers are calculated from the scatterplot of same samples.
Fig 3 Genotypes identified among the subjects having <80% of normal G6PD activity and that phenotype illustrated in relation to 30% and 70% of normal activity thresholds. CO, VC, and VL Hom are Coimbra, Viangchan, and Vanua Lava homozygous respectively. CO, VC, CT and VL Het are Coimbra, Viangchan, Chatham and Vanua Lava heterozygous respectively. VL & CT and VL & VC represent the 3 compound heterozygotes of those variants. The ND lane represent subjects negative for the G6PD variant SNPs analyzed, but not whole gene sequenced, whereas the Normal lane represents those whole gene sequenced as wild type G6PD. The black dots represent outliers calculated from the boxplot whereas the pink outliers are calculated from the scatterplot of same samples.CC BY · PubMed Central
Fig 4 Distribution of G6PD genotypes among phenotypic activity thresholds. ND-not determined, CO–Coimbra, VC–Viangchan, VL–Vanua Lava, CT–Chatham, and KP–Kaiping. Hom–homozygous mutant and Het–heterozygous. VL & CT, and VL & VC represent the compound heterozygotes.
Fig 4 Distribution of G6PD genotypes among phenotypic activity thresholds. ND-not determined, CO–Coimbra, VC–Viangchan, VL–Vanua Lava, CT–Chatham, and KP–Kaiping. Hom–homozygous mutant and Het–heterozygous. VL & CT, and VL & VC represent the compound heterozygotes.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 28 Not checked · 63 Own results and interpretations

39 more claims

Create a free account to see all 91 claims and to verify the 47 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 29

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 45 references

Research works printed but not linked: 3

  1. World Health Organization, 2015, Control and elimination of Plasmodium vivax malaria: a technical brief
  2. B Ley, 2019, Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis., PLoS Med [Internet].
  3. S Dini, The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study., BMC Med

Cited by

See all 12

Metadata

Authors
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K.
Affiliations
Eijkman Institute for Molecular Biology (ID)
Corresponding author
Satyagraha, Ari Winasti
Venue
PLOS Neglected Tropical Diseases
Published
2021-07-16
Volume
15
Issue
7
Pages
e0009610
ISSN
  • 1935-2727 (ISSN-L)
  • 1935-2735
OpenAlex
W3180860798
Cited by
12
References
45
Citations by year
2026: 3 · 2025: 1 · 2023: 3 · 2022: 2 · 2021: 3
FWCI
1.39
Type
journal article
Language
en
Open access
Locations
  • PLoS neglected tropical diseases (publishedVersion, cc-by)
  • Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • li ka shing global health programme (LG38)
  • The Wellcome Trust Asia Africa Programme
  • ministry of research, technology and higher education of the republic of indonesia
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
glucose-6-phosphate dehydrogenase deficiency, primaquine, Plasmodium vivax, radical cure, 8-aminoquinolines, hemolytic anemia, diagnostic misclassification, heterozygous females, Sumba Island
MeSH terms
Latent Infection, Adolescent, Adult, Aged, Aged, 80 and over, Antimalarials, Child, Female, Glucosephosphate Dehydrogenase, Humans, Indonesia, Plasmodium vivax, Primaquine, Gene Expression Regulation, Enzymologic, Malaria, Vivax, Genetic Predisposition to Disease, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria. https://app.cochat.ai/papers/10.1371/journal.pntd.0009610
The paper
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021). Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0009610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.